Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTTP | P55157 | 5/20 | 0.40 |
| ▸ | DRD3 | P35462 | 2/20 | 0.38 |
| ▸ | KLRK1 | P26718 | 2/20 | 0.37 |
| ▸ | MICA | Q29983 | 2/20 | 0.37 |
| ▸ | RAET1L | Q5VY80 | 2/20 | 0.37 |
| ▸ | TACR1 | P25103 | 4/20 | 0.36 |
| ▸ | SLC6A9 | P48067 | 3/20 | 0.36 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.35 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.34 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.34 |
| ▸ | TACR3 | P29371 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3238330 | 0.82 | KDM4E (0.49) | SIGMAR1 | |
| SCHEMBL3238424 | 0.81 | CTSS (0.51) | MTTPKLRK1MICARAET1LSLC6A9 | |
| SCHEMBL3230747 | 0.81 | KLRK1 (0.44) | MTTPKLRK1MICARAET1LTACR1 | |
| SCHEMBL3233194 | 0.80 | CNR1 (0.40) | — | |
| SCHEMBL3243981 | 0.80 | CRHR1 (0.46) | KLRK1MICARAET1LSLC6A9 | |
| SCHEMBL8265383 | 0.80 | CTSS (0.44) | MTTPKLRK1MICARAET1LSLC6A9 | |
| SCHEMBL3238547 | 0.79 | SMN1; SMN2 (0.48) | DRD3 | |
| SCHEMBL3243610 | 0.79 | SLC6A9 (0.48) | MTTPKLRK1MICARAET1LTACR1 | |
| SCHEMBL3832646 | 0.79 | SLC6A9 (0.52) | MTTPTACR1SLC6A9 | |
| SCHEMBL3008740 | 0.79 | SLC6A9 (0.52) | MTTPTACR1SLC6A9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7745642-B2 | Glycine transport inhibitors | GLAXO GROUP LIMITED (GB) | 2010-06-29 | — | — | US | disclosed |
| US-7745642-B2 | Glycine transport inhibitors | GLAXO GROUP LIMITED (GB) | 2010-06-29 | — | — | US | disclosed |
| US-7745642-B2 | Glycine transport inhibitors | GLAXO GROUP LIMITED (GB) | 2010-06-29 | — | — | US | disclosed |
| US-20080287547-A1 | Glycine Transport Inhibitors | GLAXO GROUP LIMITED (GB) | 2008-11-20 | — | — | US | disclosed |
| US-20080287547-A1 | Glycine Transport Inhibitors | GLAXO GROUP LIMITED (GB) | 2008-11-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080287547-A1 | Glycine Transport Inhibitors | SLC18A2, SLC6A5, SLC1A2 | MTTP 440/4885DRD3 402/4885KLRK1 1993/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.